Berman Capital Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Berman Capital Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-22	Closed	-$1K	–	2125
2021 Q2	$1K	Buy	22 +15	+214%	+$1.14K	﹤0.01%	1740
2021 Q1	$0	Buy	7 +1	+17%	+$92	﹤0.01%	1812
2020 Q4	$0	Sell	6 -13	-68%	-$1.59K	﹤0.01%	1727
2020 Q3	$2K	Hold	19	–	–	﹤0.01%	1291
2020 Q2	$3K	Buy	19 +6	+46%	+$1.24K	﹤0.01%	1135
2020 Q1	$2K	Buy	+13	New	+$2.8K	﹤0.01%	1131

Other funds holding LKFT

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Berman Capital Advisors's LKFT Position: Q3 2021 in Review

Berman Capital Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2021, closing a stake of 22 shares — an estimated $1K sold.

Berman Capital Advisors first reported a position in LKFT in Q1 2020 and held it in 6 quarters. The position peaked at $3K in Q2 2020. 81 funds tracked by Wall St. Rank hold LKFT as of Q3 2021.

Berman Capital Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2021 after selling out during the quarter.
Berman Capital Advisors sold 22 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2021, an estimated $1K.
Berman Capital Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2020 and held it in 6 quarters.
Berman Capital Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $3K in Q2 2020.
81 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.